Measures that target Russia’s core industries will depress consumption and investment
Tim Kobe, the man behind the Apple Store's signature touches, remembers what Jobs taught him about retail design
In offering conflicting opinions within hours, two federal courts have set up a fight at the Supreme Court over the Affordable Care Act
Xiaomi Chief Executive Officer Lei Jun unveils the Mi4, a metal-backed iPhone-esque smartphone with a 5-inch display, the latest Qualcomm Snapdragon chip, and a $320 price tag
A months-long public-relations debacle is taking a heavy toll on the operators of dark pools
The furniture manufacturer of midcentury classics acquires its largest retail outlet
That an accordion-playing parodist has become one of the most enduring musical acts of our time is, well, a little weird
A new report shows young college-educated professionals will wait a long time to see the financial rewards of their degree.
Profiled companies pay the recruiting service, but job-seekers don't
Founders: Dr. Mark Chandler and Craig Benson (The company was formed in 1998 as a wholly owned subsidiary of Luminex Corp. (LMNX) and subsequently spun off in 2002 as a private management-owned entity.)
VC Investment over the last four quarters: $25 million
With 95 employees worldwide, Rules-Based Medicine, a biomarker testing company, is actively developing diagnostic tests to detect the presence of complex diseases and conditions in the areas of neuropsychiatry, nephrology, immunology, and cardiology. The company is also developing what it calls the first fully closed reproducible whole-blood culture system. Despite the recession, Rules-Based Medicine's founders remain optimistic about its prospects and those of its peers that promote efficiency and cost savings for drug development and diagnostics customers.
Key to startup success: "We took a customer-focused approach to biotechnology, which drove our decision to commit resources to developing much needed comprehensive biomarker content. ... Our customers have essentially directed and funded our R&D since inception."